The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of 10-day ASTX727 (decitabine/cedazuridine) in combination with venetoclax for relapsed or refractory acute myeloid leukemia.
 
Mehmet Uyanik
No Relationships to Disclose
 
Courtney Dinardo
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Genentech/Abbvie; GlaxoSmithKline; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Molecular Partners; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER
Research Funding - Abbvie; Astex Pharmaceuticals; BeiGene; Bristol-Myers Squibb/Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; Remix Therapeutics; SERVIER
 
Maro Ohanian
No Relationships to Disclose
 
Kelly Chien
Honoraria - Abbvie
Consulting or Advisory Role - Rigel
 
Yesid Alvarado Valero
Honoraria - Astellas Pharma; Novartis
Consulting or Advisory Role - MEI Pharma
Research Funding - Astex Pharmaceuticals (Inst); BerGenBio (Inst); Daiichi Sankyo/Lilly (Inst); FibroGen (Inst); Jazz Pharmaceuticals (Inst); Sun Pharma (Inst)
 
Gautam Borthakur
Consulting or Advisory Role - Abbvie; Argenx; BiolineRx; BioTheryX; Catamaran Bio; Nkarta; Novartis; PTC Therapeutics; Takeda; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Nkarta (Inst); Nkarta (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); TCR2 Therapeutics (Inst); Treadwell Therapeutics (Inst); XBiotech (Inst)
 
Naval Daver
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)
 
Ghayas Issa
Consulting or Advisory Role - Abbvie; Kura Oncology; Novartis; NuProbe; Sanofi; Syndax
Research Funding - Astex Pharmaceuticals (Inst); Cullinan Oncology; Kura Oncology (Inst); Merck; Novartis (Inst); NuProbe (Inst); Syndax (Inst)
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma; Autolus; Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; TargetRX; Terns Pharmaceuticals
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Terns Pharmaceuticals; TGRX
Travel, Accommodations, Expenses - Aptitude Health; Autolus; Daiichi Sankyo Nordics; HMP Education; MD Education; Nucleus Global; ONVIV; Pfizer
 
Lucia Masarova
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Cogent Biosciences; Pharmaessentia
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - MorphoSys
 
Koichi Takahashi
No Relationships to Disclose
 
William Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; MDACC Cancer Center Support Grant; NIH/NCI award number CA016672; Novartis; Numab; Nurix; Oncternal Therapeutics, Inc; Pharmacyclics; Xencor
 
Corey Bradley
No Relationships to Disclose
 
Allison Pike
No Relationships to Disclose
 
Duyen Nguyen
No Relationships to Disclose
 
Farhad Ravandi-Kashani
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astellas Pharma (Inst); Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor
 
Guillermo Garcia-Manero
Honoraria - Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Consulting or Advisory Role - Ascentage Pharma; Bristol-Myers Squibb; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Research Funding - Abbvie; Bristol-Myers Squibb; Chordia Therapeutics; Curis; Genentech; Jazz Pharmaceuticals; Novartis; Rigel; Stemline Therapeutics; Taiho Oncology; Zentalis
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
 
Abhishek Maiti
Research Funding - Celgene (Inst); Chimeric Therapeutics (Inst); CytoMed Therapeutics (Inst); Indapta Therapeutics (Inst); Lin BioScience (Inst)